Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

0:00
2:14
Manda indietro di 15 secondi
Manda avanti di 15 secondi
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

Altri episodi di "Pharmaceutical Executive"